Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. - Wikidata - awgldk - TriplyDB

Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

http://www.wikidata.org/entity/Q36607127

about

Identifying Recent HIV Infections: From Serological Assays to Genomics HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus Bottlenecks in HIV-1 transmission: insights from the study of founder viruses Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus Cellular superspreaders: an epidemiological perspective on HIV infection inside the body Recent Insights into the HIV/AIDS Pandemic.Induction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike.Which Antibody Functions are Important for an HIV Vaccine?Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences.Mucosal immunity in the female genital tract, HIV/AIDS Phenotypic properties of transmitted founder HIV-1 Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins Macrophage infection via selective capture of HIV-1-infected CD4+ T cells.Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection.Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model.Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques A Novel Role for the Receptor of the Complement Cleavage Fragment C5a, C5aR1, in CCR5-Mediated Entry of HIV into Macrophages.Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness Quantifying CD4/CCR5 Usage Efficiency of HIV-1 Env Using the Affinofile System.Establishment of mouse leukemia cell lines expressing human CD4/CCR5 using lentiviral vectors.Development of SHIVs with circulating, transmitted HIV-1 variants.The HIV-1 transmission bottleneck.Nonhuman Primate Models and Understanding the Pathogenesis of HIV Infection and AIDS.HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G.Evolutionary view of the AIDS process

P2860

Q26778001-6E061E78-9477-411D-9E94-AE14F4B7C940 Q26825087-68DB48A3-A5A6-4FE2-94AF-F31DA10676F2 Q27021279-DBC19410-08D3-4C93-B323-69BA2850E38C Q28082862-2DCCA1ED-6AE9-4B83-8A3B-D5E18AF235F1 Q28551914-B5B82E1D-12A4-48F3-99B4-AD3BA53E1D4E Q28657772-89C23F0A-7789-41DB-93DE-00358984A31E Q30235024-F6CE38FE-2514-4906-AC5C-EF966716B0B0 Q30401836-7B3D5599-A6B3-4370-A2CC-697BAACC7D2D Q30654651-DCABB2AE-B9F8-4319-AEA6-01F12D5DDB0B Q33620194-3A7250AE-0704-4DAF-9DDF-D3FB0DEFDF34 Q33772637-94D058E4-34A6-477C-B905-77C076C4E17F Q34262089-18FCB947-77E2-4F76-ABFD-4BEC7C24865D Q34267043-2AF81DDE-7BB5-42EF-B4F6-BC94A9A3ED25 Q34275424-4EFB45C4-952B-4E78-A335-07AF5A2F1649 Q34336058-9D090FAD-8DFF-4622-8C21-83929FEA1251 Q34503200-47F01EE6-A0C0-41DA-AB93-691741D54192 Q34620235-802C872C-CF24-429B-A465-A9AA69695D88 Q34721189-EA62B133-D23E-44BA-9088-C92BB862C354 Q34742795-C8B51B3E-6441-4371-9B5B-B827EE6F2FC0 Q35855904-6710A4E1-4EA2-4247-9345-0F89EB5D63B7 Q35915764-8D28E2FE-7E19-477D-B9AA-EA0969CCCFB8 Q36110367-50E659BE-A517-4621-8CB6-5C305613CA04 Q36298503-08270C53-4E79-4910-B21D-42F6012EA956 Q36337888-F6344BF3-21D5-456C-8AC5-A50494E109CA Q36523998-CEDD4F1F-176B-4B6D-8A94-F32A0E96FA75 Q36756266-7FBD41F8-0293-49DB-9D7C-1A75FEBF9E63 Q36911645-CD294E71-5AE8-40A6-AEE8-815AA0FED81F Q36978861-2F148D01-BF48-41DF-94A1-071FA6D257D0 Q37123335-363EED1C-0F58-42B2-8D3D-34596DF04DBE Q37362368-B4AD2427-AF51-45A7-9793-6A667442DA91 Q37390786-B0780401-1EEB-4313-81A5-3CAFCEDA4A21 Q37444204-628A64B2-D761-4768-B556-BC1D62E2A5EA Q37612507-E4D44BD2-A1B3-4C41-B5CE-DC2DA82DC1BA Q38808224-AB60C8F2-BEE2-4B69-BCAF-0051161CD203 Q39177873-A9DB281F-829D-44FB-BD48-4A43CAF595E3 Q41144765-512642B1-848C-46A4-AF80-B35B02A9B1A6 Q42314454-561E4F53-3872-4221-A706-47B077362564 Q46243818-257FCCCD-F067-4759-9AF2-525290B90BA5 Q55033661-4453BEBE-BFD5-481D-A2BC-FB358090E896 Q58794804-192FF106-9A52-4F1A-BBDB-C0AF3A04461E

P2860

Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

http://www.wikidata.org/entity/Q36607127

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Transmitted/founder and chroni ...... ferential utilization of CCR5.

@ast

Transmitted/founder and chroni ...... ferential utilization of CCR5.

@en

type

label

Transmitted/founder and chroni ...... ferential utilization of CCR5.

@ast

Transmitted/founder and chroni ...... ferential utilization of CCR5.

@en

prefLabel

Transmitted/founder and chroni ...... ferential utilization of CCR5.

@ast

Transmitted/founder and chroni ...... ferential utilization of CCR5.

@en

P1433

Q36607127-40255BEB-B500-49F0-9C93-1A33C35B2A82

P1476

Q36607127-31EB982D-4C62-484B-9DD4-B612CFA66055

P2093

Q36607127-0B859B91-6D34-4198-ABC0-81F31191A268

Q36607127-454CC9F4-5B4E-431D-8C3F-434A28454A22

Q36607127-5510561E-01AC-4C83-B340-222F492BF421

Q36607127-556C4E98-1271-4C4D-95FA-9ABA108FDBB8

Q36607127-6B8EF2A6-130D-4EBE-AB00-15F0618F131C

Q36607127-7A77FB89-C1E5-4A9E-8036-A185555B6D9D

Q36607127-7E93620B-4161-4620-87D2-F86B40B2DE90

Q36607127-B41A046C-EF40-4B15-88BC-9B036FF83477

Q36607127-FCE5ED0B-D4F4-451B-BA4E-F210CD485C85

P2860

Q36607127-0276C8FE-23C5-4577-B1D7-A9475960454E

Q36607127-08148731-3442-4103-8504-04CCA9B3488C

Q36607127-09EA0F55-CFA3-47FE-9EDE-985AF8D8B2EA

Q36607127-0CC202A0-1F3A-4848-9D51-96F239D0982B

Q36607127-0D19197B-24D0-4AA4-9910-1C185CEDD7BA

Q36607127-105AE6F6-921C-449F-A8CF-CEF6C7653533

Q36607127-1434BAD7-32B9-4B6F-A053-ACB8824C4CDF

Q36607127-1751FAE1-1DF4-40A0-8C31-D2494ED75F7E

Q36607127-1B98B1E3-0110-42B0-A541-E5B5368B7790

Q36607127-1CFEED90-CA3A-4C7B-BBCA-68EF006756B2

P304

Q36607127-16D454FB-0857-4202-87AF-4A0D3B0F735C

P31

Q36607127-99F284D4-A88D-4937-8BC6-E696641E9222

P356

Q36607127-5114FA14-A833-45F7-B949-86BF5A8D8104

P407

Q36607127-5C2B1561-5E8F-4E94-B101-62F32D3E6776

P433

Q36607127-D0C60A88-B9C6-4626-938B-AAE939577634

P478

Q36607127-99BF969D-7E19-4A0E-827B-A21809977E8F

P50

Q36607127-8817237C-C468-419E-A262-5CA5A98398B5

Q36607127-B8D8499F-F466-4EEA-B6BB-C20C5C68E7CD

Q36607127-BDB7DF93-C38A-4DEF-A423-C1251BD5E6BC

Q36607127-E1CFB0BB-10E9-4915-BB17-028BDEC8B28E

Q36607127-FE2D5CF5-354E-489E-B742-6B0B504131F4

P577

Q36607127-F0F2864E-04A1-489B-94D7-BE546B6774D9

P5875

Q36607127-07391FC1-03CB-4A74-88A2-3A7CA1932069

P698

Q36607127-D034E6CC-ABFE-47BD-9BDD-B215C48EBBEB

P921

Q36607127-4D37EF17-6571-439D-8619-BAE5B6E12A7E

P932

Q36607127-B6CE8136-E215-414D-BA6A-36082649B713

P356

P1433

Journal of Virology

P1476

Transmitted/founder and chroni ...... ferential utilization of CCR5.

@en

P2093

Chuka A Didigu

http://www.w3.org/2001/XMLSchema#string

Fang-Hua Lee

http://www.w3.org/2001/XMLSchema#string

John P Moore

http://www.w3.org/2001/XMLSchema#string

Kelechi C Chikere

http://www.w3.org/2001/XMLSchema#string

Per Johan Klasse

http://www.w3.org/2001/XMLSchema#string

Reem Berro

http://www.w3.org/2001/XMLSchema#string

Robert W Doms

http://www.w3.org/2001/XMLSchema#string

Shilpa S Iyer

http://www.w3.org/2001/XMLSchema#string

Zahra F Parker

http://www.w3.org/2001/XMLSchema#string

P2860

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry.

Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

P304

2401-2411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02964-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Beatrice H. Hahn

Nicholas F Parrish

P577

2012-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233995531

http://www.w3.org/2001/XMLSchema#string

P698

23269796

http://www.w3.org/2001/XMLSchema#string

P921

HIV transmission

P932

3571396

http://www.w3.org/2001/XMLSchema#string